Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
doi: 10.1002/cphy.c160016 71
This study aims to enhance understanding of the neurological safety profile of GLP-1 RAs and inform clinical practice and patient care
Reduces systemic inflammation and supports conditions like leaky gut, gastritis, or IBS-related damage
MT-II is used when broader melanocortin receptor activation including central effects is the research objective
Colors denote development generation: gray = foundational pharmacology
doi: 10.3389/fnagi.2025.1601602 Received 28 March 2025 Accepted 03 July 2025 Published 24 July 2025 Volume 17 - 2025 Edited by Rita Machado De Olivera, New University of Lisbon, Portugal Reviewed by Venkateswarlu Kanamarlapudi, Swansea University Medical School, United Kingdom Joon W Shim, Marshall University, United States Updates Copyright 2025 Li, Huang, Wang, Huang, Shi, Luo and Huang
US$ 21.80
US$ 23.44
US$ 27.70
US$ 29.94
